skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiopharmaceuticals for SPECT cancer detection

Abstract

The purpose of the study was to assess the efficacy of single photon emission computed tomography (SPECT) with {sup 199}Tl and {sup 99}mTc-MIBI in the detection of breast, laryngeal and hypopharyngeal cancers. A total of 220 patients were included into the study: 120 patients with breast lesions (100 patients with breast cancer and 20 patients with benign breast tumors) and 100 patients with laryngeal/hypopharyngeal diseases (80 patients with laryngeal/hypopharyngeal cancer and 20 patients with benign laryngeal/hypopharyngeal lesions). No abnormal {sup 199}Tl uptake was seen in all patients with benign breast and laryngeal lesions, indicating a 100% specificity of {sup 199}Tl SPECT. In the breast cancer patients, the increased {sup 199}Tl uptake in the breast was visualized in 94.8% patients, {sup 99m}Tc-MIBI—in 93.4% patients. The increased {sup 199}Tl uptake in axillary lymph nodes was detected in 60% patients, and {sup 99m}Tc-MIBI—in 93.1% patients. In patients with laryngeal/hypopharyngeal cancer, the sensitivity of SPECT with {sup 199}Tl and {sup 99m}Tc-MIBI was 95%. The {sup 199}Tl SPECT sensitivity in identification of regional lymph node metastases in the patients with laryngeal/hypopharyngeal cancer was 75% and the {sup 99m}Tc-MIBI SPECT sensitivity was 17%. The data obtained showed that SPECT with {sup 199}Tl and {sup 99m}Tc-MIBI canmore » be used as one of the additional imaging methods in detection of tumors.« less

Authors:
; ; ;  [1];  [2]; ;  [3]; ;  [1]
  1. Tomsk Cancer Research Institute, Kooperativny Street 5, Tomsk, 634050 (Russian Federation)
  2. (Russian Federation)
  3. Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050 (Russian Federation)
Publication Date:
OSTI Identifier:
22608270
Resource Type:
Journal Article
Resource Relation:
Journal Name: AIP Conference Proceedings; Journal Volume: 1760; Journal Issue: 1; Conference: PC'16: International conference on physics of cancer: Interdisciplinary problems and clinical applications 2016, Tomsk (Russian Federation), 22-25 Mar 2016; Other Information: (c) 2016 Author(s); Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOMEDICAL RADIOGRAPHY; DETECTION; LYMPH; LYMPH NODES; MAMMARY GLANDS; METASTASES; NEOPLASMS; PATIENTS; PHOTON EMISSION; PHOTONS; RADIOPHARMACEUTICALS; SENSITIVITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SPECIFICITY; TECHNETIUM 99; THALLIUM 199

Citation Formats

Chernov, V. I., E-mail: chernov@oncology.tomsk.ru, Medvedeva, A. A., E-mail: tickayaAA@oncology.tomsk.ru, Zelchan, R. V., E-mail: r.zelchan@yandex.ru, Sinilkin, I. G., E-mail: sinilkinig@oncology.tomsk.ru, Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050, Stasyuk, E. S., Larionova, L. A., Slonimskaya, E. M., and Choynzonov, E. L.. Radiopharmaceuticals for SPECT cancer detection. United States: N. p., 2016. Web. doi:10.1063/1.4960230.
Chernov, V. I., E-mail: chernov@oncology.tomsk.ru, Medvedeva, A. A., E-mail: tickayaAA@oncology.tomsk.ru, Zelchan, R. V., E-mail: r.zelchan@yandex.ru, Sinilkin, I. G., E-mail: sinilkinig@oncology.tomsk.ru, Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050, Stasyuk, E. S., Larionova, L. A., Slonimskaya, E. M., & Choynzonov, E. L.. Radiopharmaceuticals for SPECT cancer detection. United States. doi:10.1063/1.4960230.
Chernov, V. I., E-mail: chernov@oncology.tomsk.ru, Medvedeva, A. A., E-mail: tickayaAA@oncology.tomsk.ru, Zelchan, R. V., E-mail: r.zelchan@yandex.ru, Sinilkin, I. G., E-mail: sinilkinig@oncology.tomsk.ru, Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050, Stasyuk, E. S., Larionova, L. A., Slonimskaya, E. M., and Choynzonov, E. L.. 2016. "Radiopharmaceuticals for SPECT cancer detection". United States. doi:10.1063/1.4960230.
@article{osti_22608270,
title = {Radiopharmaceuticals for SPECT cancer detection},
author = {Chernov, V. I., E-mail: chernov@oncology.tomsk.ru and Medvedeva, A. A., E-mail: tickayaAA@oncology.tomsk.ru and Zelchan, R. V., E-mail: r.zelchan@yandex.ru and Sinilkin, I. G., E-mail: sinilkinig@oncology.tomsk.ru and Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050 and Stasyuk, E. S. and Larionova, L. A. and Slonimskaya, E. M. and Choynzonov, E. L.},
abstractNote = {The purpose of the study was to assess the efficacy of single photon emission computed tomography (SPECT) with {sup 199}Tl and {sup 99}mTc-MIBI in the detection of breast, laryngeal and hypopharyngeal cancers. A total of 220 patients were included into the study: 120 patients with breast lesions (100 patients with breast cancer and 20 patients with benign breast tumors) and 100 patients with laryngeal/hypopharyngeal diseases (80 patients with laryngeal/hypopharyngeal cancer and 20 patients with benign laryngeal/hypopharyngeal lesions). No abnormal {sup 199}Tl uptake was seen in all patients with benign breast and laryngeal lesions, indicating a 100% specificity of {sup 199}Tl SPECT. In the breast cancer patients, the increased {sup 199}Tl uptake in the breast was visualized in 94.8% patients, {sup 99m}Tc-MIBI—in 93.4% patients. The increased {sup 199}Tl uptake in axillary lymph nodes was detected in 60% patients, and {sup 99m}Tc-MIBI—in 93.1% patients. In patients with laryngeal/hypopharyngeal cancer, the sensitivity of SPECT with {sup 199}Tl and {sup 99m}Tc-MIBI was 95%. The {sup 199}Tl SPECT sensitivity in identification of regional lymph node metastases in the patients with laryngeal/hypopharyngeal cancer was 75% and the {sup 99m}Tc-MIBI SPECT sensitivity was 17%. The data obtained showed that SPECT with {sup 199}Tl and {sup 99m}Tc-MIBI can be used as one of the additional imaging methods in detection of tumors.},
doi = {10.1063/1.4960230},
journal = {AIP Conference Proceedings},
number = 1,
volume = 1760,
place = {United States},
year = 2016,
month = 8
}
  • A method for detection and characterization of single MeV α-particle and recoil tracks in PMMA photoresist by atomic force microscopy (AFM) analysis has been demonstrated. The energy deposition along the track is shown to lead to a latent pattern in the resist due to contrast reversal. It has been shown that the pattern, consisting of conical spikes, can be developed by conventional processing as a result of the dissolution rate of poly(methyl methacrylate) (PMMA) being greater than that for the modified material in the cylindrical volume of the track core. The spikes can be imaged and counted by routine AFMmore » analysis. Investigations by angular-resolved near-grazing incidence reveal additional tracks that correspond to recoil tracks. The observations have been correlated with modelling, and shown to be in qualitative agreement with prevailing descriptions of collision cascades. The results may be relevant to technologies that are based on detection and characterization of single energetic ions. In particular, the direct visualization of the collision cascade may allow more accurate estimates of the actual interaction volume, which in turn will permit more precise assessment of dose distribution of α-emitting radionuclides used for targeted radiotherapy. The results could also be relevant to other diagnostic or process technologies based on interaction of energetic ions with matter.« less
  • One hundred sixty-seven patients with clinical State I carcinoma of the endometrium were treated primarily by operation consisting of total abdominal hysterectomy, bilateral salpingo-oophorectomy, selective pelvic and para-aortic lymphadenectomy, and cytologic testing of peritoneal washings. Twenty-six (15.5%) of the 167 patients had malignant cells identified on cytologic examinations of peritoneal washings. Recurrence developed in 10 of these 26 (34.0%) compared to 14/141 (9.9%) patients with negative cytologic testing. Of the 26 patients, 13 (50%) had disease outside of the uterus at operation and seven have died of disease (54%). Thirteen patients had malignant cells in the peritoneal washings but nomore » disease outside of the uterus and six (46%) of these have died of disseminated intra-abdominal carcinomatosis. On the basis of the poor outcome of those patients who had malignant cells in the peritoneal washings in the 167 patients studied, a plan of treating such patients with intraperitoneal radioactive chromic phosphate suspension (P-32) was instituted. Twenty-three subsequent patients with clinical Stage I carcinoma of the endometrium were found to have malignant cells in the peritoneal fluid. All 23 received intra-abdominal P-32 suspension instillation after operation. There have been three recurrences with two patients dying of disease. All of the three recurrences appeared at sites distant from the abdominal cavity. Peritoneal cytologic examination appears to be an important factor in the prognosis of endometrial cancer and, when the washings are positive for malignant cells, intraperitoneal chronic phosphate therapy appears to be efficacious.« less
  • Purpose: The aim of this work was to review new and clinical practice PET radiopharmaceuticals for prostate cancer imaging. Methods: PET radiopharmaceuticals were reviewed on the main databases. Availability, dosimetry, accuracy and limitations were considered. Results: The following radioisotopes with respective physical half-life and mean positron energy were found: {sup 18}F (109,7 min, 249,8 keV), {sup 89}Zr (78,4 hs, 395,5 keV), {sup 11}C (20,4 min, 385,7 keV) and {sup 68}Ga (67,8 min, 836 keV). {sup 68}Ga was the only one not produced by cyclotron. Radiopharmaceuticals uptake by glucose metabolism ({sup 18}F-FDG), lipogenesis ({sup 11}C-Choline and {sup 11}C-Acetate), amino acid transportmore » (Anti-{sup 18}F-FACBC), bone matrix ({sup 18}F-NaF), prostatespecific membrane antigen ({sup 68}Ga-PSMA and {sup 89}Zr-J591), CXCR receptors ({sup 89}Ga-Pentixafor), adrenal receptors ({sup 18}F-FDHT) and gastrin release peptide receptor (bombesin analogue). Most of radiopharmaceuticals are urinary excretion, so bladder is the critical organ. 11C-choline (pancreas), Anti-{sup 18}FFACBC (liver) and {sup 18}F-FBDC (stomach wall) are the exception. Higher effective dose was seen {sup 18}F-NaF (27 μSv/MBq) while the lowest was {sup 11}CAcetate (3,5 μSv/MBq). Conclusion: Even though {sup 18}F-FDG has a large availability its high urinary excretion and poor uptake to slow growing disease offers weak results for prostate cancer. Better accuracy is obtained when {sup 18}F-NaF is used for bone metastatic investigation although physicians tend to choose bone scintigraphy probably due to its cost and practice. Many guidelines in oncology consider {sup 11}C or {sup 18}F labeled with Choline the gold standard for biochemical relapse after radical treatment. Local, lymph node and distant metastatic relapse can be evaluated at same time with this radiopharmaceutical. There is no consensus over bigger urinary excretion for {sup 18}F labeling. Anti-{sup 18}F-FACBC, {sup 68}Ga-PSMA and {sup 68}Ga-Pentixafor are demonstrating good results but more researches are needed. While PSMA imaging seems to be independent of PSA level, one choline limitation, anti-{sup 18}F-FACBC adds value because imaging any disease stage. {sup 68}Ga-Petixafor is being tested as theranostics marker integrating molecular image and therapy.« less
  • The most common primary ocular tumor in adults is malignant melanoma of the choroid. Metastatic tumors to the choroid occur with the same frequency. The radioactive phosphorous uptake test is used most often as a nuclear diagnostic test. The test does not differentiate melanomas from metastases, and it is necessary to perform surgery for proper placement of a detection device within a distance of 1-2 mm of the tumor. These deficiencies leave ophthalmologists with a pressing need for a gamma-emitting radiopharmaceutical that would facilitate noninvasive identification of choroidal melanoma. This need is made more urgent by the fact that recently,more » radiation therapy has been used to treat these tumors rather than enucleation. Eyes then harbor irradiated melanoma whose status is unknown. The tumor rarely decreases in size more than 25% to 50%. There is thus a need for a specific diagnostic test to assess the nature of the tumor and the effectiveness of therapy.« less